The VHL/HIF axis in clear cell renal carcinoma

Seminars in Cancer Biology

Volumn 23, Issue 1, 2013, Pages 18-25

  Shen, Chuan ^a   Kaelin, William G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Hypoxia; Kidney cancer; VEGF; Von Hippel Lindau

Indexed keywords

CYCLIN D1; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEMETHYLASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4; ONCOPROTEIN; SCATTER FACTOR RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

AMINO TERMINAL SEQUENCE; CANCER INHIBITION; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHROMOSOME 14Q; CHROMOSOME DELETION; CLINICAL ASSESSMENT; ENZYME REGULATION; GENE CONTROL; GENETIC ANALYSIS; HUMAN; KIDNEY CARCINOMA; KWASHIORKOR; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; TUMOR XENOGRAFT;

CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84873091765     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.06.001     Document Type: Review

References (143)

1. Maher E., Kaelin W.G. von Hippel-Lindau disease. Medicine 1997, 76:381-391.
2. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. Journal of Clinical Oncology 2004, 22:4991-5004.
3. Beroukhim R., Brunet J.P., Di Napoli A., Mertz K.D., Seeley A., Pires M.M., et al. Patterns of gene expression and copy-number alterations in von Hippel-Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research 2009, 69:4674-4681.
4. Furge K.A., Tan M.H., Dykema K., Kort E., Stadler W., Yao X., et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 2007, 26:1346-1350.
5. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cells 2002, 1:459-468.
6. Montani M., Heinimann K., von Teichman A., Rudolph T., Perren A., Moch H. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. American Journal of Surgical Pathology 2010, 34:806-815.
7. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
8. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
9. Burrows A.E., Smogorzewska A., Elledge S.J. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14280-14285.
10. Xia W., Nagase S., Montia A.G., Kalachikov S.M., Keniry M., Su T., et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Research 2008, 68:1667-1674.
11. Pedersen M.T., Helin K. Histone demethylases in development and disease. Trends in Cell Biology 2010, 20:662-671.
12. Varier R.A., Timmers H.T. Histone lysine methylation and demethylation pathways in cancer. Biochimica et Biophysica Acta 2011, 1815:75-89.
13. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biology 2008, 10:361-369.
14. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Molecular and Cellular Biology 2010, 30:4595-4603.
15. Niu X., Zhang T., Liao L., Zhou L., Lindner D.J., Zhou M., et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 2012, 31:776-786.
16. Kaelin W.G. von Hippel-Lindau disease. Annual Review of Pathology: Mechanisms of Disease 2007, 2:145-173.
17. Semenza G.L. Oxygen sensing, homeostasis, and disease. New England Journal of Medicine 2011, 365:537-547.
18. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer 2002, 2:673-682.
19. Li L., Zhang L., Zhang X., Yan Q., Minamishima Y.A., Olumi A.F., et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Molecular and Cellular Biology 2007, 27:5381-5392.
20. Clifford S., Cockman M., Smallwood A., Mole D., Woodward E., Maxwell P., et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics 2001, 10:1029-1038.
21. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics 2001, 10:1019-1027.
22. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 2008, 30:393-402.
23. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. Journal of Biological Chemistry 2002, 277:32405-32408.
24. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
25. Maynard M.A., Evans A.J., Hosomi T., Hara S., Jewett M.A., Ohh M. Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB Journal 2005, 19:1396-1406.
26. Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 2003, 278:11032-11040.
27. 2 sensing. Science 2001, 292:464-468.
28. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
29. Yu F., White S., Zhao Q., Lee F. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9630-9635.
30. Epstein A., Gleadle J., McNeill L., Hewitson K., O'Rourke J., Mole D., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
31. Bruick R., McKnight S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
32. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13459-13464.
33. Kim W.Y., Safran M., Buckley M.R., Ebert B.L., Glickman J., Bosenberg M., et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO Journal 2006, 25:4650-4662.
34. Liu Y.V., Baek J.H., Zhang H., Diez R., Cole R.N., Semenza G.L. RACK1 competes with HSP90 for binding to HIF-1α and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Molecular Cell 2007, 25:207-217.
35. Koh M.Y., Darnay B.G., Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Molecular and Cellular Biology 2008, 28:7081-7095.
36. Bento C.F., Fernandes R., Ramalho J., Marques C., Shang F., Taylor A., et al. The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS One 2010, 5:e15062.
37. Lando D., Peet D., Gorman J., Whelan D., Whitelaw M., Bruick R. FIH-1 is a an asparaginyl hydroxylase that regulates the transcriptional activity of hypoxia inducible factor. Genes and Development 2002, 16:1466-1471.
38. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. Journal of Biological Chemistry 2002, 277:26351-26355.
39. Mahon P., Hirota K., Semenza G. FIH-1: a novel protein that interacts with HIF-1 a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes and Development 2001, 15:2675-2686.
40. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. Journal of Biological Chemistry 2004, 279:9899-9904.
41. Stolze I.P., Tian Y.M., Appelhoff R.J., Turley H., Wykoff C.C., Gleadle J.M., et al. Genetic analysis of the role of the asparaginyl hydroxylase FIH in regulating HIF transcriptional target genes. Journal of Biological Chemistry 2004, 279:42719-42725.
42. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Research 2006, 66:3688-3698.
43. Bracken C.P., Fedele A.O., Linke S., Balrak W., Lisy K., Whitelaw M.L., et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. Journal of Biological Chemistry 2006, 281:22575-22585.
44. Yan Q., Bartz S., Mao M., Li L., Kaelin W.G. The hypoxia-inducible factor 2{alpha} N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Molecular and Cellular Biology 2007, 27:2092-2102.
45. Carroll V.A., Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Research 2006, 66:6264-6270.
46. Hu C.J., Sataur A., Wang L., Chen H., Simon M.C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Molecular Biology of the Cell 2007, 18:4528-4542.
47. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes and Development 2006, 20:557-570.
48. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 2005, 25:5675-5686.
49. Baba M., Hirai S., Yamada-Okabe H., Hamada K., Tabuchi H., Kobayashi K., et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 2003, 22:2728-2738.
50. Zatyka M., da Silva N.F., Clifford S.C., Morris M.R., Wiesener M.S., Eckardt K.U., et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Research 2002, 62:3803-3811.
51. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Research 2002, 62:3014-3019.
52. Shen C., Beroukhim R., Schumacher S.E., Zhou J., Chang M., Signoretti S., et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discovery 2011, 1:222-235.
53. Gordan J.D., Lal P., Dondeti V.R., Letrero R., Parekh K.N., Oquendo C.E., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cells 2008, 14:435-446.
54. Maxwell P., Weisner M., Chang G-W., Clifford S., Vaux E., Pugh C., et al. The von Hippel-Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor α subunits. Nature 1999, 399:271-275.
55. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biology 2003, 1:439-444.
56. Zimmer M., Doucette D., Siddiqui N., Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Molecular Cancer Research 2004, 2:89-95.
57. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cells 2002, 1:237-246.
58. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cells 2002, 1:247-255.
59. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Molecular and Cellular Biology 2005, 25:3163-3172.
60. Rankin E.B., Rha J., Selak M.A., Unger T.L., Keith B., Liu Q., et al. HIF-2 regulates hepatic lipid metabolism. Molecular and Cellular Biology 2009, 29:4527-4538.
61. Rankin E.B., Rha J., Unger T.L., Wu C.H., Shutt H.P., Johnson R.S., et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 2008, 27:5354-5358.
62. Rankin E.B., Biju M.P., Liu Q., Unger T.L., Rha J., Johnson R.S., et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. Journal of Clinical Investigation 2007, 117:1068-1077.
63. Purdue M.P., Johansson M., Zelenika D., Toro J.R., Scelo G., Moore L.E., et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics 2011, 43:60-65.
64. Klatte T., Rao P.N., de Martino M., LaRochelle J., Shuch B., Zomorodian N., et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. Journal of Clinical Oncology 2009, 27:746-753.
65. Monzon F.A., Alvarez K., Peterson L., Truong L., Amato R.J., Hernandez-McClain J., et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Modern Pathology 2011, 24:1470-1479.
66. Morris M.R., Hughes D.J., Tian Y.M., Ricketts C.J., Lau K.W., Gentle D., et al. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Research 2009, 29:4337-4343.
67. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
68. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cells 2003, 4:133-146.
69. Zhang J., Chen G.Q. Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. Pathophysiology 2009, 16:297-303.
70. Zhang J., Song L.P., Huang Y., Zhao Q., Zhao K.W., Chen G.Q. Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica 2008, 93:1480-1487.
71. Song L.P., Zhang J., Wu S.F., Huang Y., Zhao Q., Cao J.P., et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2008, 27:519-527.
72. Abdollahi A. LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions. Journal of Cellular Physiology 2007, 210:16-25.
73. Lemeta S., Salmenkivi K., Pylkkanen L., Sainio M., Saarikoski S.T., Arola J., et al. Frequent loss of heterozygosity at 6q in pheochromocytoma. Human Pathology 2006, 37:749-754.
74. Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic umor growth and progression. Nature Reviews Cancer 2011, 12:9-22.
75. Bertout J.A., Majmundar A.J., Gordan J.D., Lam J.C., Ditsworth D., Keith B., et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14391-14396.
76. Roberts A.M., Watson I.R., Evans A.J., Foster D.A., Irwin M.S., Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Research 2009, 69:9056-9064.
77. Nickols N.G., Jacobs C.S., Farkas M.E., Dervan P.B. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chemical Biology 2007, 2:561-571.
78. Viger A., Dervan P.B. Exploring the limits of benzimidazole DNA-binding oligomers for the hypoxia inducible factor (HIF) site. Bioorganic and Medicinal Chemistry 2006, 14:8539-8549.
79. Vinson C. A rationally designed small molecule that inhibits the HIF-1alpha-ARNT heterodimer from binding to DNA in vivo. Science's STKE 2005, 2005:pe23.
80. Olenyuk B.Z., Zhang G.J., Klco J.M., Nickols N.G., Kaelin W.G., Dervan P.B. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:16768-16773.
81. Lee K., Zhang H., Qian D.Z., Rey S., Liu J.O., Semenza G.L. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:17910-17915.
82. Zimmer M., Ebert B.L., Neil C., Brenner K., Papaioannou I., Melas A., et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Molecular Cell 2008, 32:838-848.
83. Grkovic T., Whitson E.L., Rabe D.C., Gardella R.S., Bottaro D.P., Linehan W.M., et al. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2alpha induced gene expression. Bioorganic and Medicinal Chemistry Letters 2011, 21:2113-2115.
84. Bokesch H.R., Gardella R.S., Rabe D.C., Bottaro D.P., Linehan W.M., McMahon J.B., et al. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chemical and Pharmaceutical Bulletin 2011, 59:1178-1179.
85. Woldemichael G.M., Vasselli J.R., Gardella R.S., McKee T.C., Linehan W.M., McMahon J.B. Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. Journal of Biomolecular Screening 2006, 11:678-687.
86. Zimmer M., Lamb J., Ebert B.L., Lynch M., Neil C., Schmidt E., et al. The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. Cancer Research 2010, 70:3071-3079.
87. Kim W.Y., Kaelin W.G. Molecular pathways in renal cell carcinoma-rationale for targeted treatment. Seminars in Oncology 2006, 33:588-595.
88. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
89. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007, 356:2271-2281.
90. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T., Gutkind J.S. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Research 2008, 68:1144-1153.
91. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cells 2007, 12:9-22.
92. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of HIF1alpha and HIF2alpha on mTORC1 and mTORC2. Journal of Biological Chemistry 2008, 283:34495-34499.
93. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 2006, 66:1500-1508.
94. Tremblay F., Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. Journal of Biological Chemistry 2001, 276:38052-38060.
95. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clinical Cancer Research 2010, 16:3628-3638.
96. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
97. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356:125-134.
98. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 356:115-124.
99. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 2010, 28:1061-1068.
100. Hutson T.E., Davis I.D., Machiels J.P., De Souza P.L., Rottey S., Hong B.F., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2010, 28:475-480.
101. Sosman J., Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009, 115:2368-2375.
102. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009, 27:1432-1439.
103. Rini B.I., Garcia J.A., Cooney M.M., Elson P., Tyler A., Beatty K., et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. Journal of Clinical Oncology 2010, 28:e284-e285. [author reply e6-7].
104. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
105. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation 1999, 103:159-165.
106. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 2003, 111:1287-1295.
107. Vuky J., Isacson C., Fotoohi M., dela Cruz J., Otero H., Picozzi V., et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Investigational New Drugs 2006, 24:85-88.
108. Polite B.N., Desai A.A., Manchen B., Stadler W.M. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single-institution phase II trial. Clinical Genitourinary Cancer 2006, 4:275-280.
109. Ramp U., Reinecke P., Gabbert H., Gerharz C. Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types. European Journal of Cancer 2000, 36:932-941.
110. Ramp U., Jaquet K., Reinecke P., Schardt C., Friebe U., Nitsch T., et al. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. Journal of Urology 1997, 157:2345-2350.
111. Merseburger A.S., Hennenlotter J., Simon P., Kruck S., Koch E., Horstmann M., et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Research 2005, 25:1901-1907.
112. Moch H., Sauter G., Buchholz N., Gasser T.C., Bubendorf L., Waldman F.M., et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Human Pathology 1997, 28:1255-1259.
113. Uhlman D.L., Nguyen P., Manivel J.C., Zhang G., Hagen K., Fraley E., et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clinical Cancer Research 1995, 1:913-920.
114. Mydlo J., Michaeli J., Cordon-Cardo C., Goldenberg A., Heston W., Fair W. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Research 1989, 49:3407-3411.
115. Lau J., Fowler J.J., Ghosh L. Epidermal growth factor in the normal and neoplastic kidney and bladder. Journal of Urology 1988, 139:170-175.
116. Petrides P., Bock S., Bovens J., Hofmann R., Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Research 1990, 50:3934-3939.
117. Knebelmann B., Ananth S., Cohen H., Sukhatme V. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Research 1998, 58:226-231.
118. Wang Y., Roche O., Yan M.S., Finak G., Evans A.J., Metcalf J.L., et al. Regulation of endocytosis via the oxygen-sensing pathway. Nature Medicine 2009, 15:319-324.
119. Franovic A., Holterman C.E., Payette J., Lee S. Human cancers converge at the HIF-2alpha oncogenic axis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21306-21311.
120. Franovic A., Gunaratnam L., Smith K., Robert I., Patten D., Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13092-13097.
121. Smith K., Gunaratnam L., Morley M., Franovic A., Mekhail K., Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Research 2005, 65:5221-5230.
122. Dawson N.A., Guo C., Zak R., Dorsey B., Smoot J., Wong J., et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clinical Cancer Research 2004, 10:7812-7819.
123. Hainsworth J.D., Spigel D.R., Sosman J.A., Burris H.A., 3rd, Farley C., Cucullu H. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clinical Genitourinary Cancer 2007, 5:427-432.
124. Bukowski R.M., Kabbinavar F.F., Figlin R.A., Flaherty K., Srinivas S., Vaishampayan U., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Journal of Clinical Oncology 2007, 25:4536-4541.
125. Rowinsky E.K., Schwartz G.H., Gollob J.A., Thompson J.A., Vogelzang N.J., Figlin R., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Journal of Clinical Oncology 2004, 22:3003-3015.
126. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
127. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20932-20937.
128. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
129. Koochekpour S., Jeffers M., Wang P., Gong C., Taylor G., Roessler L., et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Molecular and Cellular Biology 1999, 19:5902-5912.
130. Nakaigawa N., Yao M., Baba M., Kato S., Kishida T., Hattori K., et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Research 2006, 66:3699-3705.
131. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cells 2003, 3:347-361.
132. Bommi-Reddy A., Almeciga I., Sawyer J., Geisen C., Li W., Harlow E., et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16484-16489.
133. Zhang Y.W., Staal B., Essenburg C., Su Y., Kang L., West R., et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Research 2010, 70:6880-6890.
134. Grady B., Goharderakhshan R., Chang J., Ribeiro-Filho L.A., Perinchery G., Franks J., et al. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. Journal of Urology 2001, 166:1088-1092.
135. Kasahara T., Bilim V., Hara N., Takahashi K., Tomita Y. Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Anticancer Research 2006, 26:4299-4305.
136. Schraml P., Struckmann K., Bednar R., Fu W., Gasser T., Wilber K., et al. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. American Journal of Pathology 2001, 158:593-601.
137. Stadler W.M., Vogelzang N.J., Amato R., Sosman J., Taber D., Liebowitz D., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. Journal of Clinical Oncology 2000, 18:371-375.
138. Krieg A.J., Rankin E.B., Chan D., Razorenova O., Fernandez S., Giaccia A.J. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Molecular and Cellular Biology 2010, 30:344-353.
139. Xia X., Lemieux M.E., Li W., Carroll J.S., Brown M., Liu X.S., et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:4260-4265.
140. Sar A., Ponjevic D., Nguyen M., Box A.H., Demetrick D.J. Identification and characterization of demethylase JMJD1A as a gene upregulated in the human cellular response to hypoxia. Cell and Tissue Research 2009, 337:223-234.
141. Wellmann S., Bettkober M., Zelmer A., Seeger K., Faigle M., Eltzschig H.K., et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochemical and Biophysical Research Communications 2008, 372:892-897.
142. Pollard P., Loenarz C., Mole D., McDonough M., Gleadle J., Schofield C., et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochemical Journal 2008, 416:387-394.
143. Beyer S., Kristensen M.M., Jensen K.S., Johansen J.V., Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. Journal of Biological Chemistry 2008, 283:36542-36552.